NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in Japan

  NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in Japan

    Close collaboration with Omron Healthcare in preparation of the Filing

Business Wire

WALTHAM, Mass. -- March 11, 2014

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the
treatment and management of the neurological complications of diabetes,
reported the regulatory submission for NC-stat DPNCheck^® in Japan. NC-stat
DPNCheck is a rapid, accurate and quantitative point-of-care test to detect
diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians
to select appropriate treatment. DPN is the most common complication of
diabetes, affecting over half of people with diabetes. DPN causes significant
morbidity including pain, increased risk of falling in the elderly, and is the
primary trigger for diabetic foot ulcers which may require lower extremity
amputations.

The submission was prepared in close collaboration with Omron Healthcare Co.,
Ltd, NeuroMetrix’ partner for NC-stat DPNCheck in Japan and other Asia
markets. The submission seeks marketing certification for a Class II
Designated Controlled Medical Device as defined in the technical standards of
the Japan Ministry of Health, Labor, and Welfare. Clearance of the submission
will allow NC-stat DPNCheck to be marketed within Japan.

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and
point-of-care devices for the treatment and management of chronic pain,
peripheral neuropathies, and associated neurological disorders. The Company is
presently focused on diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers
that may require amputation and cause disabling chronic pain. The annual cost
of diabetic neuropathies has been estimated at $14 billion in the United
States. The company markets the SENSUS^™ Pain Management System for treating
chronic pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck^® device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to guide
treatment. For more information, please visit http://www.DPNCheck.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.